Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This study found that black cohosh extract BNO 1055 reduced testosterone-induced prostate and seminal vesicle growth in rats, suggesting it may contain potent 5α-reductase inhibitors useful for prostate cancer prevention.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study identified several gonadal hormone drugs, including toremifene citrate, tamoxifen citrate, and clomiphene citrate, that effectively inhibited filovirus entry in a pseudovirus model.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study suggests that young women with low prolactin levels may face higher cardiometabolic risk, and reducing cabergoline dosage reversed related metabolic disturbances.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This article reviews the problem of acne and hirsutism in women, highlighting the effectiveness of combined oral contraceptives containing drospirenone and levomefolate calcium in managing these conditions and polycystic ovary syndrome, but no new clinical results are reported.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

This study found that topical estradiol inhibits hair growth in mice by preventing the hair follicle's transition from resting to growth phase, a process reversible with an estrogen receptor antagonist.

The authors reported that both finasteride and oral contraceptives with drospirenone had a significant therapeutic effect on women with polycystic ovary syndrome, leading to pregnancies in both treatment groups.

This study compared letrozole and clomiphene citrate for ovulation induction in women with polycystic ovary syndrome and found that while clomiphene led to more follicles, monofollicular development and endometrial thickness were higher with letrozole, and pregnancy rates did not significantly differ between the two treatments.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This study found that Cinobufacin combined with chemotherapy improved clinical outcomes in breast cancer patients and reduced certain side effects compared to chemotherapy alone.

This review discusses the diagnosis and treatment of hyperandrogenism in women, emphasizing that cyproterone acetate is effective for severe hirsutism, though it reports no new clinical findings.